LEMAITRE VASCULAR INC 8K

LeMaitre Vascular reported strong Q1 2026 results, issued higher Q2 and full-year 2026 guidance, declared a $0.25 quarterly dividend, and highlighted a $100 million share repurchase authorization.

LeMaitre Vascular, Inc. reported strong preliminary unaudited Q1 2026 financial results with 11% year-over-year sales growth to $66.6 million (10% organic), gross margin expansion to 72.7%, operating income up 41% to $17.8 million, and EPS up 42% to $0.68, driven by higher pricing, manufacturing efficiencies, and robust product and geographic performance. The company raised its outlook by issuing Q2 and full-year 2026 guidance calling for approximately 11–12% sales growth and 26% adjusted EPS growth, while also highlighting significant product line gains (including 36% growth in Artegraft and double-digit growth in grafts, valvulotomes, and carotid shunts) and record sales across EMEA, APAC, and the Americas. In addition, the board approved a quarterly cash dividend of $0.25 per share payable June 4, 2026 to stockholders of record on May 21, 2026, and previously authorized a share repurchase program of up to $100 million of common stock on February 19, 2026, effective through February 18, 2027 unless extended, providing for capital returns alongside ongoing operational and earnings growth, with management also discussing use of non-GAAP financial measures and related reconciliations.

Filing Facts

CIK

1158895

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-206578

Alert Tier

7